 - Clinical AWARE-1 trial achieves primary endpoint and confirms that pelareorep is an immunotherapeutic agent which synergizes with checkpoint inhibitors: Validation of clinical development strategy in breast cancer - Phase 2 BRACELET-1 breast cancer trial remains on track for full enrollment in Q4 2021 - Highly encouraging clinical proof-of-concept data in metastatic pancreatic cancer demonstrate pelareoreps broad applicability to a number of different tumor types - Strong financial foundation with approximately 50.8 million in cash on hand and cash runway into 2023 - Management hosting conference call and webcast today at 8:00 a.m. ET SAN DIEGO and CALGARY, AB, Aug. 6, 2021 PRNewswire -- Oncolytics Biotech Inc. NASDAQ: ONCY TSX: ONC today announced its financial results and development highlights for the quarter ended June 30, 2021. 